<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01300208</url>
  </required_header>
  <id_info>
    <org_study_id>CC-11050-CLE-002</org_study_id>
    <nct_id>NCT01300208</nct_id>
  </id_info>
  <brief_title>To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus</brief_title>
  <official_title>A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first study in cutaneous lupus erythematosus subjects to evaluate the safety,
      tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CC-11050.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory values from chemistry, hematology, urinalysis, inflammation/immunology panel that reveal clinically significant abnormalities and that may constitute a safety concern</measure>
    <time_frame>Up to 21 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Up to 21 weeks</time_frame>
    <description>To describe the area under the curve (AUC) of CC-11050 and M15 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the clinical response rate of CC-11050 in subjects with discoid lupus erythematosus or sub acute lupus erythematosus using the Cutaneous Lupus Area and Severity Index Activity Score following 12-weeks of treatment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Up to 21 weeks</time_frame>
    <description>To describe the peak serum concentration (Cmax) of CC-11050 and M15 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Up to 21 weeks</time_frame>
    <description>To describe the lowest serum concentration (Cmin)of CC-11050 and M15 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Up to 21 weeks</time_frame>
    <description>To describe the time after administration of a drug when the maxiumum plasma concentration is reached (tmax) of CC-11050 and M15 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Up to 21 weeks</time_frame>
    <description>To describe the half life (t1/2) of CC-11050 and M15 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Up to 21 weeks</time_frame>
    <description>To describe the oral clearance (CL/F) of CC-11050 and M15 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>Up to 21 weeks</time_frame>
    <description>To describe the volume of distribution (Vz/F) of CC-11050 and M15 in plasma</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cutaneous Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-11050 (50 milligrams twice per day and Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-11050 (100 milligrams twice per day and Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-11050 (200 milligrams twice per day and Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-11050</intervention_name>
    <description>Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subjects with a clinical diagnosis of discoid lupus erythematosus or sub acute lupus
             erythematosus for &gt; 16 weeks prior to screening and consistent histological findings
             on skin biopsy based on Gilliam classification who are candidates for systemic
             therapies (as determined by the Investigator)

          -  Must, in the opinion of the Investigator, have active skin lesions of sufficient
             severity at Screening and Baseline (a Cutaneous Lupus Area and Severity Index Activity
             Score of ≥ 10)

          -  All subjects taking hydroxychloroquine, chloroquine or quinacrine during the study
             must have documentation of an ophthalmologic exam performed within 24 weeks of the
             Baseline Visit.

          -  Must meet the following laboratory criteria:

               -  White blood cell count ≥3000/mm3 (≥ 3.0 x 109/L) and &lt; 14,000/mm3 (&lt; 14 x 109/L)

               -  Absolute neutrophil count (ANC) &gt; 1500 cells/μL (1.5 x 109/L)

               -  Platelet count ≥ 100,000/μL (≥ 100 x 109/L)

               -  Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)

               -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT)

               -  ≤ 1.5 X upper limit of normal (ULN)

               -  Total bilirubin &lt; 2mg/dL

               -  Hemoglobin &gt; 11 g/dL Key Exclusion Criteria

          -  Participation in multiple CC-11050 cohorts or previous exposure to CC-11050

          -  Presence or history of SLE based on investigators' clinical evaluation where subject
             exhibits medically significant (as determined by the Investigator) LE-related
             pleuritis, pericarditis, neurologic, renal and/or other major SLE-related organ system
             involvement(SLE-related to SLE joint involvement is acceptable).

          -  Use of topical or any local therapy known to possibly benefit discoid lupus
             erythematosus or SCLE sub acute lupus erythematosus within 2 weeks of the Screening
             Visit

          -  Use of concomitant disease modifying anti-rheumatic drugs (DMARDs) with the exception
             of anti-malarials within 4 weeks of screening- Use of topical or any local therapy
             known to possibly benefit discoid lupus erythematosus or SCLE sub acute lupus
             erythematosus within 2 weeks of the Screening Visit

          -  Use of immunosuppressives (eg, azathioprine, mycophenolate mofetil, methotrexate,
             etc.) within 4 weeks of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tong Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwest Arkansas Clinical Trials Center, PLLC</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medderm Associates</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univ. School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peachtree Dermatology Associates Research Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Medaphase Inc</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Advanced Aesthetics</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology, P.C.</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Dermatology</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <disposition_first_submitted>September 25, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 25, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 25, 2013</disposition_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cutaneous lupus erythematosus</keyword>
  <keyword>subacute lupus erythematosus</keyword>
  <keyword>discoid lupus erythematosus</keyword>
  <keyword>lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Lupus Erythematosus, Cutaneous</mesh_term>
    <mesh_term>Lupus Erythematosus, Discoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

